autologous platelet-rich plasma + gonadotropins

This is a **combination therapy** comprising **autologous platelet-rich plasma (PRP)** and **gonadotropins**, typically used as an investigational adjunct in reproductive medicine, particularly for women with poor ovarian response or diminished ovarian reserve. - **Autologous PRP** is derived from the patient's own blood via centrifugation, resulting in plasma with a high concentration of platelets and associated growth factors, including PDGF, TGF-β, FGF, VEGF, EGF, and IGF. These factors contribute to tissue healing, angiogenesis, and regeneration. In reproductive use, intraovarian injection aims to improve ovarian reserve markers, follicle development, and oocyte yield by enhancing ovarian angiogenesis, folliculogenesis, and reducing local inflammation[1][2][3][4][5][7]. - **Gonadotropins** are exogenous hormones (typically recombinant FSH or HMG) that directly stimulate ovarian follicle growth, supporting stimulation protocols in assisted reproduction cycles and inducing ovulation. Together, the **combination is hypothesized to provide synergistic effects**: PRP may boost ovarian repair and follicle development via growth factors, while gonadotropins drive follicle maturation and ovulation. This approach is under clinical study to improve outcomes for patients with poor ovarian response in IVF/ART cycles[2][4][6].

Other names

autologous PRP + gonadotropinsautologous platelet-rich plasma plus gonadotropins